Iqvia Holdings Inc (NYSE:IQV) Stock Position Raised by Rosenblum Silverman Sutton S F Inc. CA

Rosenblum Silverman Sutton S F Inc. CA lifted its stake in shares of Iqvia Holdings Inc (NYSE:IQV) by 32.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,604 shares of the medical research company’s stock after acquiring an additional 7,296 shares during the quarter. Iqvia accounts for 1.8% of Rosenblum Silverman Sutton S F Inc. CA’s portfolio, making the stock its 25th largest holding. Rosenblum Silverman Sutton S F Inc. CA’s holdings in Iqvia were worth $4,763,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. lifted its holdings in shares of Iqvia by 12.0% in the first quarter. BlackRock Inc. now owns 12,290,692 shares of the medical research company’s stock valued at $1,768,016,000 after purchasing an additional 1,313,508 shares in the last quarter. FMR LLC lifted its holdings in shares of Iqvia by 27.5% in the first quarter. FMR LLC now owns 5,376,239 shares of the medical research company’s stock valued at $773,372,000 after purchasing an additional 1,158,248 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Iqvia by 18.2% in the first quarter. AQR Capital Management LLC now owns 3,642,793 shares of the medical research company’s stock valued at $519,972,000 after purchasing an additional 561,276 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Iqvia by 19.3% in the second quarter. Janus Henderson Group PLC now owns 3,630,639 shares of the medical research company’s stock valued at $584,166,000 after purchasing an additional 588,179 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Iqvia by 8.4% in the fourth quarter. Geode Capital Management LLC now owns 2,130,570 shares of the medical research company’s stock valued at $247,087,000 after purchasing an additional 164,811 shares in the last quarter. 90.38% of the stock is owned by institutional investors and hedge funds.

A number of analysts have recently issued reports on IQV shares. Barclays set a $180.00 target price on Iqvia and gave the company a “buy” rating in a report on Monday, July 15th. Leerink Swann started coverage on Iqvia in a report on Tuesday, May 28th. They issued an “outperform” rating and a $136.38 target price for the company. Morgan Stanley increased their target price on Iqvia from $156.00 to $170.00 and gave the company an “overweight” rating in a report on Wednesday, June 19th. William Blair restated an “outperform” rating on shares of Iqvia in a report on Wednesday, June 19th. Finally, Mizuho upgraded Iqvia from a “neutral” rating to a “buy” rating and increased their target price for the company from $150.00 to $175.00 in a report on Friday, June 21st. Three equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the stock. Iqvia presently has a consensus rating of “Buy” and an average target price of $161.13.

In other news, insider Ari Bousbib sold 96,000 shares of the firm’s stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $160.00, for a total value of $15,360,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Kevin C. Knightly sold 6,945 shares of the firm’s stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $158.53, for a total value of $1,100,990.85. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 198,945 shares of company stock worth $30,860,991. 6.00% of the stock is currently owned by company insiders.

Iqvia stock traded down $1.55 during mid-day trading on Monday, hitting $154.45. 920,732 shares of the company’s stock were exchanged, compared to its average volume of 1,005,122. The company has a debt-to-equity ratio of 1.72, a quick ratio of 1.14 and a current ratio of 1.14. The firm has a market capitalization of $30.97 billion, a PE ratio of 30.17, a P/E/G ratio of 1.93 and a beta of 0.88. Iqvia Holdings Inc has a 1-year low of $104.90 and a 1-year high of $164.13. The business has a 50 day moving average price of $158.13.

Iqvia (NYSE:IQV) last posted its earnings results on Wednesday, July 24th. The medical research company reported $1.39 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.38 by $0.01. The firm had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.70 billion. Iqvia had a net margin of 2.31% and a return on equity of 15.95%. The business’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.29 earnings per share. Analysts expect that Iqvia Holdings Inc will post 5.86 EPS for the current fiscal year.

Iqvia Company Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Further Reading: Why do corrections happen?

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit